| __timestamp | Dynavax Technologies Corporation | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 59644696 |
| Thursday, January 1, 2015 | 22180000 | 79541000 |
| Friday, January 1, 2016 | 37257000 | 98015000 |
| Sunday, January 1, 2017 | 27367000 | 103958000 |
| Monday, January 1, 2018 | 64770000 | 103654000 |
| Tuesday, January 1, 2019 | 74986000 | 128951000 |
| Wednesday, January 1, 2020 | 79256000 | 135799000 |
| Friday, January 1, 2021 | 100156000 | 149883000 |
| Saturday, January 1, 2022 | 131408000 | 220206000 |
| Sunday, January 1, 2023 | 152946000 | 265542000 |
Infusing magic into the data realm
In the ever-evolving landscape of biotechnology, understanding operational costs is crucial for strategic planning. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Dynavax Technologies Corporation and Travere Therapeutics, Inc. over the past decade, from 2014 to 2023.
Dynavax has seen a steady increase in SG&A expenses, starting at approximately $18 million in 2014 and reaching around $153 million by 2023. This represents a growth of over 750%, highlighting the company's expanding operational scale and investment in administrative capabilities.
Travere's SG&A expenses have also surged, beginning at nearly $60 million in 2014 and climbing to approximately $266 million in 2023. This increase of over 340% underscores Travere's commitment to scaling its operations and enhancing its market presence.
Both companies reflect the broader trend in the biotech sector, where strategic investments in operational infrastructure are pivotal for sustained growth.
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Who Optimizes SG&A Costs Better? Incyte Corporation or Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Dynavax Technologies Corporation
Selling, General, and Administrative Costs: Rhythm Pharmaceuticals, Inc. vs Dynavax Technologies Corporation
Operational Costs Compared: SG&A Analysis of Veracyte, Inc. and Travere Therapeutics, Inc.
HUTCHMED (China) Limited or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Ligand Pharmaceuticals Incorporated vs Dynavax Technologies Corporation: SG&A Expense Trends
Iovance Biotherapeutics, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Dynavax Technologies Corporation and Novavax, Inc.
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.